Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
Androdias G, Lünemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Bsteh G, Butzkueven H, Ciccarelli O, Cobo-Calvo A, Derfuss T, Di Pauli F, Edan G, Enzinger C, Geraldes R, Granziera C, Hacohen Y, Hartung HP, Hynes S, Inglese M, Kappos L, Kuusisto H, Langer-Gould A, Magyari M, Marignier R, Montalban X, Mycko MP, Nourbakhsh B, Oh J, Oreja-Guevara C, Piehl F, Prosperini L, Sastre-Garriga J, Sellebjerg F, Selmaj K, Siva A, Tallantyre E, van Pesch V, Vukusic S, Weinstock-Guttman B, Zipp F, Tintoré M, Iacobaeus E, Stankoff B. Androdias G, et al. Among authors: hartung hp. Brain. 2024 Dec 21:awae409. doi: 10.1093/brain/awae409. Online ahead of print. Brain. 2024. PMID: 39707906
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
Hartung HP, Benedict RHB, Berger T, Bermel RA, Brochet B, Carroll WM, Freedman MS, Holmøy T, Karabudak R, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Wuerfel J, Clinch S, Kadner K, Kuenzel T, Kulyk I, Raposo C, Thanei GA, Killestein J. Hartung HP, et al. Neurology. 2024 Dec 24;103(12):e210049. doi: 10.1212/WNL.0000000000210049. Epub 2024 Dec 3. Neurology. 2024. PMID: 39626127 Clinical Trial.
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
Meuth SG, Wolff S, Mück A, Willison A, Kleinschnitz K, Räuber S, Pawlitzki M, Konen FF, Skripuletz T, Grothe M, Ruck T, Huttner HB, Kleinschnitz C, Bopp T, Pul R, Cree BAC, Hartung HP, Möllenhoff K, Pfeuffer S. Meuth SG, et al. Among authors: hartung hp. Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143. Online ahead of print. Ann Neurol. 2024. PMID: 39582359
Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.
Alvarez E, Steinman L, Fox EJ, Hartung HP, Qian P, Wray S, Robertson D, Selmaj K, Wynn D, Mok K, Xu Y, Bodhinathan K, Miskin HP, Cree BAC. Alvarez E, et al. Among authors: hartung hp. Front Neurol. 2024 Oct 24;15:1473284. doi: 10.3389/fneur.2024.1473284. eCollection 2024. Front Neurol. 2024. PMID: 39512280 Free PMC article.
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.
Schwake C, Ladopoulos T, Häußler V, Kleiter I, Ringelstein M, Aktas O, Kümpfel T, Engels D, Havla J, Hümmert MW, Kretschmer JR, Tkachenko D, Trebst C, Ayroza Galvão Ribeiro Gomes AB, Pröbstel AK, Korporal-Kuhnke M, Wildemann B, Jarius S, Pul R, Pompsch M, Krämer M, Then Bergh F, Gödel C, Schwarz P, Kowarik MC, Rommer PS, Vardakas I, Senel M, Winkelmann A, Retzlaff N, Weber MS, Husseini L, Walter A, Schindler P, Bellmann-Strobl J, Paul F, Gold R, Ayzenberg I; Neuromyelitis Optica Study Group (NEMOS). Schwake C, et al. J Neurol Neurosurg Psychiatry. 2024 Nov 4:jnnp-2024-334863. doi: 10.1136/jnnp-2024-334863. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39496464 Free article.
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials.
Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A. Derfuss T, et al. Among authors: hartung hp. Ther Adv Neurol Disord. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39399100 Free PMC article.
MS treatment de-escalation: review and commentary.
Selmaj K, Hartung HP, Mycko MP, Selmaj I, Cross AH. Selmaj K, et al. Among authors: hartung hp. J Neurol. 2024 Oct;271(10):6426-6438. doi: 10.1007/s00415-024-12584-x. Epub 2024 Aug 2. J Neurol. 2024. PMID: 39093335 Free PMC article. Review.
Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
Quint P, Schroeter CB, Kohle F, Öztürk M, Meisel A, Tamburrino G, Mausberg AK, Szepanowski F, Afzali AM, Fischer K, Nelke C, Räuber S, Voth J, Masanneck L, Willison A, Vogelsang A, Hemmer B, Berthele A, Schroeter M, Hartung HP, Pawlitzki M, Schreiber S, Stettner M, Maus U, Meuth SG, Stascheit F, Ruck T. Quint P, et al. Among authors: hartung hp. J Neurol. 2024 Sep;271(9):5930-5943. doi: 10.1007/s00415-024-12548-1. Epub 2024 Jul 11. J Neurol. 2024. PMID: 38990346 Free PMC article.
1,138 results